Phreesia Faces Class Action Lawsuit Following Revenue Guidance Cut

The legal action follows a sharp decline in Phreesia’s market value earlier this year. On March 30, 2026, the company slashed its revenue growth projections for fiscal year 2027, citing worsening macroeconomic visibility and a cooling in pharmaceutical marketing commitments within its Network Solutions segment. Investors reacted aggressively to the announcement, driving the stock price down $3.03—a 26.56% drop—to close at $8.38 on March 31, 2026.

Pomerantz LLP is spearheading the case, inviting shareholders who acquired securities during the relevant window to come forward. The firm, which maintains a global presence, claims the company misled stakeholders regarding its operational health. Interested parties can contact Danielle Peyton at 646-581-9980 or via email to participate in the litigation process.